Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.

ABSTRACT:

Objectives

In 2013, the herpes zoster (HZ) immunisation programme was introduced in the UK, recommending vaccination of adults 70 years of age (YOA) with the zoster vaccine live (ZVL), the only vaccine available at the time. The recently approved adjuvanted recombinant zoster vaccine (RZV) has a substantially different clinical profile that may offer additional benefits.This study aimed to 1) assess the public health impact (PHI) of introducing RZV in the UK compared with the current vaccination strategy and 2) explore via scenario analyses the optimal age group of vaccination in terms of PHI.

Design

A previously developed health economic model was adapted to the UK setting.

Setting

Calculations were based on efficacy data from pivotal clinical trials, HZ incidence an

SUBMITTER: van Oorschot DAM 

PROVIDER: S-EPMC6502027 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature